Abstract:Early detection is critical for effective management of Alzheimer's disease (AD) and screening for mild cognitive impairment (MCI) is common practice. Among several deep-learning techniques that have been applied to assessing structural brain changes on magnetic resonance imaging (MRI), convolutional neural network (CNN) has gained popularity due to its superb efficiency in automated feature learning with the use of a variety of multilayer perceptrons. Meanwhile, ensemble learning (EL) has shown to be beneficial in the robustness of learning-system performance via integrating multiple models. Here, we proposed a classifier ensemble developed by combining CNN and EL, i.e., the CNN-EL approach, to identify subjects with MCI or AD using MRI: i.e., classification between (1) AD and healthy cognition (HC), (2) MCIc (MCI patients who will convert to AD) and HC, and (3) MCIc and MCInc (MCI patients who will not convert to AD). For each binary classification task, a large number of CNN models were trained applying a set of sagittal, coronal, or transverse MRI slices; these CNN models were then integrated into a single ensemble. Performance of the ensemble was evaluated using stratified fivefold cross-validation method for 10 times. The number of the intersection points determined by the most discriminable slices separating two classes in a binary classification task among the sagittal, coronal, and transverse slice sets, transformed into the standard Montreal Neurological Institute (MNI) space, acted as an indicator to assess the ability of a brain region in which the points were located to classify AD. Thus, the brain regions with most intersection points were considered as those mostly contributing to the early diagnosis of AD. The result revealed an accuracy rate of 0.84 ± 0.05, 0.79 ± 0.04, and 0.62 ± 0.06, respectively, for classifying AD vs. HC, MCIc vs. HC, and MCIc vs. MCInc, comparable to previous reports and a 3D deep learning approach (3D-SENet) based on a more state-of-the-art and popular Squeeze-and-Excitation Networks model using channel attention mechanism. Notably, the intersection points accurately located the medial temporal lobe and several other structures of the limbic system, i.e., brain regions known to be struck early in AD. More interestingly, the classifiers disclosed multiple patterned MRI changes in the brain in AD and MCIc, involving these key regions. These results suggest that as a data-driven method, the combined CNN and EL approach can locate the most discriminable brain regions indicated by the trained ensemble model while the generalization ability of the ensemble model was maximized to successfully capture AD-related brain variations early in the disease process; it can also provide new insights into understanding the complex heterogeneity of whole-brain MRI changes in AD. Further research is needed to examine the clinical implication of the finding, capability of the advocated CNN-EL approach to help understand and evaluate an individual subject's disease status, symptom burden and progress, and the generalizability of the advocated CNN-EL approach to locate the most discriminable brain regions in the detection of other brain disorders such as schizophrenia, autism, and severe depression, in a data-driven way.

Alzheimer's disease early screening and staged detection with plasma proteome using machine learning and convolutional neural network

Early Diagnosis of Alzheimer's Disease Using Deep Learning

High-Performance Plasma Biomarker Panel for Alzheimer's Disease Screening Using a Femtomolar-Level Label-Free Biosensing System

Early Diagnosis of Alzheimer’s Disease Based on Selective Kernel Network with Spatial Attention

P3‐054: Biomarkers for Early Detection of Alzheimer's Disease: Plasma Proteomic Study of Early to Mild Stages of Alzheimer's Disease

Early Stage Identification of Alzheimer's Disease Using a Two-stage Ensemble Classifier

A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer's Disease

Alzheimer’s Disease Early Diagnostic and Staging Biomarkers Revealed by Large-Scale Cerebrospinal Fluid and Serum Proteomic Profiling

Alzheimer's disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling

Novel plasma protein biomarkers: A time-dependent predictive model for Alzheimer's disease

Precise Prediction of Cerebrospinal Fluid Amyloid Beta Protein for Early Alzheimer's Disease Detection Using Multimodal Data

Introducing an ensemble method for the early detection of Alzheimer's disease through the analysis of PET scan images

A Single Model Deep Learning Approach for Alzheimer’s Disease Diagnosis

Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China

Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population

Integrated Algorithm Combining Plasma Biomarkers and Cognitive Assessments Accurately Predicts Brain Β-Amyloid Pathology

Machine learning in neurological disorders: A multivariate LSTM and AdaBoost approach to Alzheimer's disease time series analysis

Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma.

Early Detection of Alzheimer's Disease Using Magnetic Resonance Imaging: A Novel Approach Combining Convolutional Neural Networks and Ensemble Learning

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma Proteomics

Diagnostic AI Modeling and Pseudo Time Series Profiling of AD and PD Based on Individualized Serum Proteome Data